Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Gastric Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 13 articles: HTML format

Single Articles

April 2025
1. WALCH HS, Borpatragohain R, Jee J, Chatila W, et al
   Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer.
   Clin Cancer Res. 2025 Apr 29:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-3473.
   PubMed     Abstract available
   
   
   March 2025
2. LIM SH, An M, Lee H, Heo YJ, et al
   Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial.
   Clin Cancer Res. 2025 Mar 18:OF1-OF15. doi: 10.1158/1078-0432.CCR-24-3528.
   PubMed     Abstract available
   
   
   January 2025
3. WANG L, Sun M, Li J, Wan L, et al
   Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial.
   Clin Cancer Res. 2025;31:74-86.
   PubMed     Abstract available
   
   
   December 2024
4. MENG QH, Halfdanarson TR, Bornhorst JA, Jann H, et al
   Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.
   Clin Cancer Res. 2024;30:5559-5567.
   PubMed     Abstract available
   
   
   
5. SKUBLENY D, Purich K, McLean DR, Martins-Filho SN, et al
   The Tumor Immune Microenvironment Drives Survival Outcomes and Therapeutic Response in an Integrated Molecular Analysis of Gastric Adenocarcinoma.
   Clin Cancer Res. 2024;30:5385-5398.
   PubMed     Abstract available
   
   
   October 2024
6. YOON C, Park DJ, Schmidt B, Thomas NJ, et al
   Retraction: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance.
   Clin Cancer Res. 2024;30:4803.
   PubMed    
   
   
   September 2024
7. BARRETT AM, Britton ZT, Carrasco RA, Breen S, et al
   Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer.
   Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-24-1853.
   PubMed     Abstract available
   
   
   July 2024
8. TOBIAS J, Maglakelidze M, Andric Z, Ryspayeva D, et al
   Phase II trial of HER-Vaxx, a B cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients under platinum-based chemotherapy (HERIZON).
   Clin Cancer Res. 2024 Jul 19. doi: 10.1158/1078-0432.CCR-24-0742.
   PubMed     Abstract available
   
   
   March 2024
9. WEI Q, Yang T, Zhu J, Zhang Z, et al
   Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration.
   Clin Cancer Res. 2024;30:984-997.
   PubMed     Abstract available
   
   
   February 2024
10. CAO L, Zhou J, Zhang J, Wu S, et al
    Editor's Note: Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and its Nuclear Accumulation Suppresses Gastric Tumorigenesis.
    Clin Cancer Res. 2024;30:918.
    PubMed    
    
    
    January 2024
11. KAWAZOE A, Yamamoto N, Sugimoto N, Kawakami H, et al
    Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
    Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-1768.
    PubMed     Abstract available
    
    
    October 2023
12. KLEMPNER SJ, Lee KW, Shitara K, Metges JP, et al
    ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2023;29:3882-3891.
    PubMed     Abstract available
    
    
    July 2023
13. MARON SB, Chatila W, Walch H, Chou JF, et al
    Determinants of survival in HER2+ metastatic esophagogastric cancer.
    Clin Cancer Res. 2023 Jul 5:CCR-22-3769. doi: 10.1158/1078-0432.CCR-22-3769.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.